Tesamorelin & CJC-1295 & Ipamorelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Tesamorelin & CJC-1295 & Ipamorelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

FDA-approved synthetic GHRH analog that stimulates pulsatile GH release; indicated to reduce excess visceral fat in HIV-associated lipodystrophy.

Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase via Gs coupling and elevating intracellular cAMP. This drives both synthesis and pulsatile secretion of endogenous growth hormone (GH), preserving hypothalamic-pituitary feedback regulation. Circulating GH subsequently stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1), which mediates downstream metabolic effects including visceral lipolysis and promotion of lean body mass. Because the peptide acts upstream at the pituitary rather than supplying exogenous GH directly, physiological pulsatility and axis feedback are maintained.

Molar mass

5136 g/mol

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• CADTH Clinical Review Report: Tesamorelin (Egrifta) — systematic review of 3 included studies — Anchoring systematic review (tesamorelin monotherapy for HIV-associated excess visceral adipose tissue); component-level, not blend-level.
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs) — Component monograph review (tesamorelin only).
• Teichman et al. 2006 — Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults (J Clin Endocrinol Metab) — Studied the WITH-DAC (long-acting, albumin-binding) analog specifically — NOT the no-DAC "Mod GRF 1-29" form sold in this blend. Kept only for GHRH-receptor mechanism/pathway context; not PK evidence for this blend's CJC-1295 component, and not blend-level.
• Dominikowski et al. 2026 — narrative review on GH/IGF-1-axis-modulating peptides (Front Endocrinol; PMID 42395176) — States the no-DAC "Mod GRF 1-29" form actually used in this blend is essentially uncharacterised in the peer-reviewed human literature, with no controlled human trials — the basis for not asserting a no-DAC half-life figure anywhere in this overlay. Component-level, not blend-level.
• Henninge et al. 2010 — Identification of CJC-1295 in an unknown pharmaceutical preparation (Drug Test Anal) — Doping-control analytical identification; states CJC-1295 is a Prohibited Substance under WADA Prohibited List Section S2. Does not distinguish DAC vs no-DAC form; component-level, not blend-level.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) injection is the dominant and best-characterized research route for tesamorelin; IV was used as the PK reference route for ipamorelin only. No controlled PK trial exists for the no-DAC CJC-1295 component or for the blend as a combined product.

Phase 3 RCTs in HIV-infected adults with lipodystrophy; single- and multiple-dose PK characterized in healthy adults and HIV patients without lipodystrophy following 2 mg SC administration

Bioavailability: FDA label states extent of absorption (AUC) was characterized after 2 mg SC; mean elimination half-life ~8 minutes in healthy subjects after SC administration of 1.4 mg (2 mg/vial formulation). Absolute SC bioavailability value not numerically stated in label.

Subcutaneous injection (abdominal site) is the only FDA-approved route for tesamorelin (EGRIFTA/EGRIFTA SV). No oral, intranasal, IV, or IM route appears in the efficacy record or labeling. Component-level, not blend-level.

No controlled human or animal pharmacokinetic trial has been identified for the no-DAC "Mod GRF 1-29" form actually sold in this blend. The only published human RCT bearing the 'CJC-1295' name (Teichman et al., J Clin Endocrinol Metab 2006) studied the WITH-DAC, long-acting, albumin-binding analog — a pharmacologically distinct product not used here.

Bioavailability: No peer-reviewed pharmacokinetic data exists for the no-DAC form used in this blend. It is understood qualitatively as short-acting relative to the DAC-conjugated analog (whose own trials report a multi-day half-life via albumin binding), but no no-DAC-specific half-life or bioavailability figure is established in the peer-reviewed literature (PMID 42395176) — no number is asserted.

Do not conflate with the DAC-conjugated CJC-1295 RCT (Teichman et al. 2006), cited elsewhere for GHRH-receptor mechanism context only — that study characterizes a different, long-acting product. A commonly repeated '~30 minute half-life' figure for the no-DAC form is not supported by peer-reviewed literature and is deliberately not asserted here (fail-closed per PMID 42395176's own characterization of this form as uncharacterised). Component-level, not blend-level.

Randomized, placebo-controlled, dose-escalation PK/PD study in healthy human volunteers; 15-minute IV infusion at five dose levels (4.21–140.45 nmol/kg)

Bioavailability: IV infusion used to characterize baseline PK/PD; short terminal half-life of approximately 2 hours reported. (IV route defines 100% reference bioavailability for this peptide.)

The foundational human PK/PD model for ipamorelin (Gobburu et al., Pharm Res 1999) used intravenous infusion as the reference route. IV is the only human parenteral route with published PK data for ipamorelin. Component-level, not blend-level.

Comparative PK study (animal model) evaluating nasal absorption of ipamorelin and related GHRPs

Bioavailability: After intranasal application, bioavailability of ipamorelin was estimated at approximately 20% (lower than comparator peptides NNC 26-0235, NNC 26-0194, and GHRP-2 at ~50%).

Intranasal absorption of ipamorelin was characterized in a preclinical comparative study (Johansen et al., Xenobiotica 1998). No human intranasal PK data have been published; this is an animal-derived bioavailability estimate, not a human absorption figure. Component-level, not blend-level.

De-identified aggregate community reports of SC injection of tesamorelin/CJC-1295/ipamorelin blends; no published clinical trial of the combined blend

Bioavailability: No PK data exist for the three-peptide blend as a combined product; community reports describe SC injection of reconstituted blends without quantitative bioavailability.

Community route data are aggregate and de-identified; no first-party dosing or efficacy is implied. The blend itself has no FDA-approved or clinically studied combined formulation.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $9.08 · median $9.67 · p75 $10.00 · 6 researched vendors

Legit, COA-backed band: $6.00–$10.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$60

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Independent Janoshik HPLC testing of individual components from Chameleon Peptides (Batch 002, verified live 2026-07-16): CJC-1295 no-DAC (Mod GRF 1-29) 99.624% purity (4.57mg actual vs a 5mg label); CJC-1295 DAC 98.178% purity (5.72mg actual). Blend reports (CJC-1295 no-DAC + Ipamorelin) reported identity + amount only (purity not included on blend reports). A separate vendor (Eternal Peptides) advertises Janoshik-tested ≥99% purity for a CJC-1295 no-DAC + Ipamorelin blend. No independent purity data located for tesamorelin within a three-way blend.

Independent labs cited for this compound

One recall identified: Tailor Made Compounding LLC voluntary recall of tesamorelin products (Jul–Sep 2018) due to incorrect BUD labeling. No recalls found specifically for a branded 'Tesamorelin & CJC-1295 & Ipamorelin Blend' product.

Buyer red-flag checklist

• CJC-1295 and Ipamorelin are not on the FDA 503A bulks list, are not components of FDA-approved drugs, and have no USP monograph — compounded products containing them are not eligible for 503A exemptions (per FDA Warning Letter to Tailor Made Compounding, 2020).
• Tesamorelin is FDA-approved only as Egrifta (for HIV-associated lipodystrophy); grey-market bulk tesamorelin acetate sold as a 'research chemical' outside the approved drug channel raises the same regulatory questions FDA has raised for other unapproved bulk peptide APIs.
• A Chinese peptide-API manufacturer (Hangzhou Yiqi Biotechnology) was placed on FDA Import Alert 66-40 (Jan 30, 2026) after a CGMP warning letter citing process-validation, analytical-method-validation, and stability failures — general supply-chain risk context for the peptide-API market; the letter does not name this blend's specific components.
• Research-grade peptide products sold online lack medical-grade purity and quality controls and are not intended for human consumption (per multiple vendor disclaimers and industry analyses).
• Health Canada warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming CJC-1295, ipamorelin, and related products.
• Blend vials combine three separate peptides; independent testing typically reports per-component identity/amount but blend-level purity is often not assessed, increasing risk of undetected impurities or misproportioning.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Janoshik amount testing of Chameleon Peptides CJC-1295 no-DAC (Mod GRF 1-29) + Ipamorelin blend (labeled 5mg/5mg; verified live 2026-07-16) showed Ipamorelin 5.61 mg and 4.86 mg, CJC-1295 no-DAC 5.12 mg and 5.07 mg across two vials (B002A/B002B) — amounts near or slightly above label, not indicative of systematic underdosing in this small sample. This is a 2-component (CJC-1295 no-DAC + Ipamorelin) report, not the 3-component tesamorelin blend. No large-scale independent aggregate underdosing prevalence statistic was located for this specific three-way blend.

• FDA Import Alert 66-40 ('Detention Without Physical Examination of Drugs and Drug Products ... from Firms Not in Compliance with Applicable Drug GMP Requirements') authorizes DWPE at the US border for firms on its Red List. Hangzhou Yiqi Biotechnology Co., Ltd was placed on this alert January 30, 2026, per its own CGMP warning letter (see quality.events) — but that letter does not name BPC-157, CJC-1295, ipamorelin, or tesamorelin, so no compound-specific import-alert linkage is established for this blend; included as general China-based peptide-API supply-chain context only.66-40
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

All three components — tesamorelin, CJC-1295, and ipamorelin — are listed on the WADA Prohibited List under S2.2.4 (Growth Hormone Releasing Factors), including GHRH and its analogues (e.g., CJC-1293, CJC-1295, sermorelin, tesamorelin) and growth hormone secretagogues (e.g., ipamorelin). Prohibited at all times (in- and out-of-competition). Both DAC and no-DAC forms of CJC-1295 are covered.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Vendor-affiliated clinic blogs promoting blends with efficacy claims
• Self-selection bias — positive outcome reports overrepresented
• Anecdotal reports without controls or baseline bloodwork
• Inexperienced user dosing confusion inflates neutral question volume
• Survivorship bias — users with severe reactions may post disproportionately
• Peptide Sciences shutdown event may skew vendor reliability discussion

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only three-peptide blend of the GHRH analogs Tesamorelin and CJC-1295 (Mod GRF 1-29) with the growth hormone secretagogue Ipamorelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet